Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase 1 Randomized Clinical TrialLeyi Lin, Stephen J. Thomas, Naomi Aronson et al.|The Journal of Infectious Diseases|2020Cited by 24
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trialKirsten E. Lyke, Robert Edelman, Joel V. Chua et al.|The Lancet Infectious Diseases|2024Cited by 24
Safety and Immunogenicity of an AS03B-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized StudyLeyi Lin, Alexander C. Schmidt, Kirsten E. Lyke et al.|American Journal of Tropical Medicine and Hygiene|2020Cited by 17
Priming with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition of multiple flaviviruses without boosting antibody responses induced by an inactivated Zika virus vaccineYifan Li, Morgane Rolland, Michael Koren et al.|EBioMedicine|2023Cited by 8